Friday, July 11, 2025

Creating liberating content

India Ratings and Research (Ind-Ra) has upgraded Reliance Infrastructure’s credit

Niagara Falls is one of the most stunning natural wonders

Related News

India’s net direct tax collections declined 1.34% year-on-year to Rs 5.63 lakh crore as of July 10, dragged down by a sharp surge in refunds, according to government data released

India Ratings and Research (Ind-Ra) has upgraded Reliance Infrastructure’s credit rating by three notches — from ‘IND D’ to ‘IND B / Stable / IND A4’ — on its non-fund

India’s foreign exchange reserves declined by $3.049 billion to $699.736 billion for the week ended July 4, according to data released by the Reserve Bank of India (RBI) on Friday.This

Niagara Falls is one of the most stunning natural wonders in the world, it’s a fact that no one can deny. Though it’s beautiful in every season, when winter takes

Jensen Huang, CEO of Nvidia, holds a motherboard as he speaks during the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France,

US stocks opened lower on Friday, pulling major indexes off their record highs from the previous session, as investor sentiment turned cautious following President Donald Trump’s fresh tariff announcements.The S&P

Trending News

India’s net direct tax collections declined 1.34% year-on-year to Rs 5.63 lakh crore as of July 10, dragged down by a sharp surge in refunds, according to government data released

India’s foreign exchange reserves declined by $3.049 billion to $699.736 billion for the week ended July 4, according to data released by the Reserve Bank of India (RBI) on Friday.This

TCS had previously disclosed in April that salary increases would be postponed due to business uncertainties. (AI image) Employees of Tata Consultancy Services (TCS) will have to wait a little

‘The Best You’ features India’s comedy queen, Bharti Singh, who shares her story resilience and reinvention Klook, Asia’s leading platform for travel experiences and services, launched its new campaign titled

Britain’s economy contracted for the second consecutive month in May, dealing a blow to finance minister Rachel Reeves as she navigates a shaky domestic recovery and heightened global uncertainty. Official

Slow US-China trade deal may push Trump’s tariff deadlines Trade deals between the US and China are moving at a pace slower than expected, which may lead to extensions of

Sun Pharma elevates Kirti Ganorkar as MD; Dilip Shanghvi to stay on as exec chairman

Word Count: 701 | Estimated Reading Time: 4 minutes


Sun Pharma elevates Kirti Ganorkar as MD; Dilip Shanghvi to stay on as exec chairman
Dilip Shanghvi & Kirti Ganorkar (From left to right)

NEW DELHI: Sun Pharma announced that its India business head, Kirti Ganorkar will be elevated as the company’s managing director to succeed the founder, Dilip Shanghvi, effective September 1. The move is part of a structured and forward-looking succession planning process at Sun Pharma, underscoring the organisation’s commitment to leadership continuity and strategic governance, a company statement said. Ganorkar, who has been heading the India business since June 2019, will now lead the company’s entire business including all its geographies, and functions. Shanghvi will continue to chair the board as executive chairman, while his son Aalok, who recently became the chief operating officer, has been additionally entrusted with the responsibility for the North America business. Shanghvi, the 69-year-old founder, will focus on strengthening Sun Pharma’s specialty portfolio and provide insights towards shaping the company’s long-term strategyGanorkar’s appointment is subject to shareholder approval at the upcoming annual general meeting. He has held various leadership roles across business development, marketing, M&A, project management, IP and litigation at Sun Pharma. A chemical engineer and MBA, he joined Sun Pharma in 1996.In another development, Abhay Gandhi – president & CEO, North America, has decided to pursue his interests outside Sun Pharma, the statement says. Further, Richard Ascroft will be joining as CEO – North America, succeeding Gandhi. Richard, a seasoned biopharmaceutical executive, most recently, served as senior VP and business unit head of the US plasma-derived therapies at Takeda Pharma, and was a member of both the US and global executive leadership teams.

Key Milestones under Shanghvi’s tenure

1983: Sun Pharma was established1991: First R&D Center, Sun Pharma Advanced Research Center (SPARC) set up in Gujarat1994: Launched IPO, oversubscribed 55 times1997: First international acquisition, Caraco Pharmaceutical Laboratories facilitated entry into US2010: Launched first generic version cancer drug, DOXOrubicin Hydrochloride in US2015: Acquired Ranbaxy in a $4 billion landmark transaction to become the world’s 5th largest specialty generic pharma company and No. 1 in India2018: Launched innovative product, Ilumya (tildrakizumab-asmn) in US2022: Global revenues crossed US$5 billion2025: Acquired Checkpoint Therapeutics, an immunotherapy and targeted oncology company, for $ 355 million





Source link

Sign In

Welcome ! Log into Your Account